Abstract | BACKGROUND: PATIENTS/METHODS:
Insulin-resistant, nondiabetic individuals with untreated OSA were randomized (2:1) to pioglitazone (45 mg/day) or placebo for eight weeks in this single-blind study. All individuals had repeat measurements pertaining to sleep (overnight polysomnography and functional outcomes of sleep questionnaire) and insulin action ( insulin suppression test). RESULTS: A total of 45 overweight/obese men and women with moderate/severe OSA were randomized to pioglitazone (n = 30) or placebo (n = 15). Although insulin sensitivity increased 31% among pioglitazone-treated compared with no change among individuals receiving placebo (p <0.001 for between-group difference), no improvement in quantitative or qualitative sleep measurements was observed. CONCLUSIONS:
Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period. These findings do not support a causal role for insulin resistance in the pathogenesis of OSA.
|
Authors | Alice Liu, Sun H Kim, Danit Ariel, Fahim Abbasi, Cindy Lamendola, James Cardell, Shiming Xu, Shailja Patel, Vanessa Tomasso, Hafasa Mojaddidi, Kaylene Grove, Philip S Tsao, Clete A Kushida, Gerald M Reaven |
Journal | Sleep medicine
(Sleep Med)
Vol. 22
Pg. 57-60
(06 2016)
ISSN: 1878-5506 [Electronic] Netherlands |
PMID | 27544837
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2016 Elsevier B.V. All rights reserved. |
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Thiazolidinediones
- Pioglitazone
|
Topics |
- Blood Glucose
(analysis)
- Fasting
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin Resistance
(physiology)
- Male
- Middle Aged
- Obesity
(physiopathology)
- Pilot Projects
- Pioglitazone
- Polysomnography
(methods)
- Single-Blind Method
- Sleep Apnea, Obstructive
(physiopathology)
- Surveys and Questionnaires
- Thiazolidinediones
(therapeutic use)
|